Nutriband Inc. to Showcase Innovations at Emerging Growth Virtual Conference
TL;DR
Nutriband's CEO presentation at the Noble Capital Markets’ conference offers investors a unique opportunity to gain insights into the company's innovative AVERSA technology and its market potential.
Nutriband will present at the Emerging Growth Virtual Equity Conference, detailing its AVERSA abuse-deterrent technology for transdermal patches, with a webcast available post-event for review.
Nutriband's development of abuse-deterrent fentanyl patches with AVERSA technology aims to reduce drug misuse, contributing to safer communities and better public health outcomes.
Discover Nutriband's breakthrough AVERSA technology at the Noble Capital Markets’ conference, a game-changer in preventing abuse of transdermal pharmaceutical products.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB), a leader in the development of transdermal pharmaceutical products, has announced its participation in the Noble Capital Markets Emerging Growth Virtual Equity Conference. CEO Gareth Sheridan will lead a fireside-style Q&A session on June 5, offering insights into the company's innovative AVERSA(TM) technology. This event underscores Nutriband's commitment to addressing the critical issue of drug abuse through its abuse-deterrent fentanyl patch, a significant step forward in pharmaceutical safety.
The presentation, accessible via webcast post-event, represents a pivotal moment for Nutriband to engage with investors and the broader pharmaceutical community. The company's focus on preventing the abuse, misuse, and accidental exposure of potent drugs through its AVERSA technology highlights the growing importance of safety innovations in the pharmaceutical industry. Nutriband's participation in this conference not only showcases its technological advancements but also its potential to make a substantial impact on public health and safety.
Curated from InvestorBrandNetwork (IBN)
